Abstract | AIMS: MATERIALS AND METHODS: RESULTS: Clinically relevant weight-loss differences were observed across all BMI subgroups, with a trend towards higher absolute weight loss with higher baseline BMI. Overall, 15.2% to 24.0% and 21.5% to 27.2% of subjects experienced nausea or vomiting with semaglutide 0.5 and 1.0 mg, respectively, versus 6.0% to 14.1% with comparators. Only 0.07 to 0.5 kg of the treatment difference between semaglutide and comparators was mediated by nausea or vomiting (indirect effects). CONCLUSIONS:
|
Authors | Bo Ahrén, Stephen L Atkin, Guillaume Charpentier, Mark L Warren, John P H Wilding, Sune Birch, Anders Gaarsdal Holst, Lawrence A Leiter |
Journal | Diabetes, obesity & metabolism
(Diabetes Obes Metab)
Vol. 20
Issue 9
Pg. 2210-2219
(09 2018)
ISSN: 1463-1326 [Electronic] England |
PMID | 29766634
(Publication Type: Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Copyright | © 2018 The Authors. Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd. |
Chemical References |
- Hypoglycemic Agents
- Insulin Glargine
- semaglutide
- Glucagon-Like Peptides
- Exenatide
- Sitagliptin Phosphate
|
Topics |
- Adult
- Aged
- Body Mass Index
- Diabetes Mellitus, Type 2
(blood, drug therapy)
- Exenatide
(therapeutic use)
- Female
- Glucagon-Like Peptides
(therapeutic use)
- Humans
- Hypoglycemic Agents
(therapeutic use)
- Insulin Glargine
(therapeutic use)
- Male
- Middle Aged
- Nausea
(chemically induced)
- Sitagliptin Phosphate
(therapeutic use)
- Treatment Outcome
- Vomiting
(chemically induced)
- Weight Loss
(drug effects)
|